In 2024, under the policy of “innovative drugs” being written into the government work report for the first time, the number of innovative drug management lines and asset quality of China’s biomedical market will continue to break through, and become an important pole of the global pharmaceutical market, opening the prelude to the global competition of local innovative drugs. In this milestone year, the multinational pharmaceutical company Astellas, which has been in China for 30 years, has also ushered in a crucial turning point. The appointment of the first local “leader” Zhao Ping injects new development momentum into the enterprise – internal cultural transformation and upgrading, continuous improvement of external influence and reputation, and acceleration of localization strategy Furthermore, for the first time, Astellai has included enhancing the capabilities of its Chinese team as a key focus of the group. It has achieved multiple accomplishments in China, including continuous approval ...
Last year, German biotechnology company BioNTech spent less than $1 billion to acquire a Chinese company’s investigational cancer drug, which was sold for over $11 billion in just six months. According to public statements from both companies, BMS will collaborate with BioNTech to develop and commercialize a tumor drug called BNT327, which is a bispecific antibody drug targeting PD-L1 and VEGF-A for the treatment of various solid tumors. BNT327 was acquired by BioNTech last year through the acquisition of Chinese biotechnology company Pumis Biotech. Last November, BioNTech acquired Pumis Biotech for only $800 million, and with the subsequent milestone payment of $150 million, the entire acquisition transaction was less than $1 billion. BioNTech has thus acquired full global ownership of BNT327. Currently, BNT327 is undergoing clinical trials as a first-line treatment for extensive stage small cell lung cancer and non-small cell lung cancer. So far, over 1000 patients have received ...
For 30 years, pediatrician Tammy Camp, MD, of Lubbock, Texas, never once encountered a case of measles on the job. Now, that’s all changed. As she told colleagues last week, that’s not all that’s different in West Texas, the epicenter of the 2025 measles outbreak in the Southwest. “We’re seeing mothers who are scared, crying in the clinic because they have a baby that they have delivered just 6 weeks ago and they know that the child is too young to receive a measles vaccine,” she said in a National Academy of Medicine update about the outbreak. “Yet, they know they need to return to work because they are responsible for putting food on the table for the rest of their family members.” To make matters more complicated, Camp has to worry about disease transmission in her clinic. While Lubbock is 90 miles from the outbreak’s rural ground zero ...
By Stephanie Brown HealthDay ReporterMONDAY, June 2, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of signs and symptoms of dry eye disease. Currently, dry eye disease treatment options are limited due to slow therapeutic onset, patient dissatisfaction, and poor adherence. Tryptyr works by stimulating corneal sensory nerves to rapidly increase natural tear production. The ophthalmic solution will be available in single-dose vials with a recommended dosage of one drop in each eye twice a day. Approval of Tryptyr was based on the results of two phase 3 clinical trials (COMET-2 and COMET-3). More than 930 patients with a history of dry eye disease were randomly assigned (1:1) to Tryptyr or vehicle. As early as day 1, Tryptyr delivered statistically significant natural tear production. Patients taking Tryptyr (versus vehicle) experienced a ≥10-mm increase in ...
June 3, Alphamab Oncology Pharmaceuticals (09966) announced that it recently presented the latest research results of JSKN003 at the 2025 ASCO Annual Meeting. The study conducted a summary analysis of the efficacy and safety of multiple indications, mainly including a Phase I clinical study in patients with advanced/metastatic solid tumors, involving different doses of JSKN003. As of February 28, 2025, a total of 46 PROC patients participated in the study. Among them, 91.3% of patients had tumor shrinkage, the objective response rate (ORR) was 63.0%, the median progression-free survival (mPFS) was 7.7 months, and the 9-month overall survival rate (OS) was 89.9%. In HER2 IHC 0 patients, the ORR was 52.4%, and in HER2 IHC 1+, 2+, and 3+ patients, the ORR was 72.2%. In terms of safety, 19.6% of patients experienced grade 3 or 4 treatment-related adverse events (TRAEs), but no deaths caused by TRAEs occurred. In addition, the ...
Huadong Medicine(000963) announced on June 3 that the marketing authorization application for ranibizumab injection (R&D code HJY28) submitted by the company’s wholly-owned subsidiary Hangzhou Sino-US East China Pharmaceutical Co., Ltd. was accepted. Ranibizumab injection is indicated in adults for the treatment of wet (neovascular) age-related macular degeneration (AMD), the treatment of visual impairment caused by diabetic macular edema (DME), the treatment of diabetic retinopathy (DR) [proliferative diabetic retinopathy (PDR) and moderate to severe non-proliferative diabetic retinopathy (NPDR)], the treatment of visual impairment caused by macular edema secondary to retinal vein occlusion (RVO) (branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)), and the treatment of visual impairment caused by choroidal neovascularization (CNV, i.e. CNV secondary to pathological myopia (PM) and other causes). Ranibizumab injection is indicated for premature infants for the treatment of retinopathy of prematurity (ROP) in zone I (stage 1+, 2+, 3 or 3+), zone II ...
Recently, Lemborexant, a dual orexin receptor antagonist originally developed by Eisai, was approved for marketing by the National Medical Products Administration, marking the official entry of China’s insomnia treatment field into the “dual orexin antagonist era.” Global sales exceeded 2.6 billion yuan Unlike traditional sedative hypnotic drugs, Lebrexan competitively binds to orexin type 1 receptor (OX1R) and type 2 receptor (OX2R), precisely inhibiting orexin-mediated wakefulness drive, thereby inducing natural sleep. In addition, unlike traditional GABA-A hypnotic drugs that inhibit rapid eye movement sleep (REM), Lebrexan can simultaneously extend the duration of non-rapid eye movement sleep (NREM) and REM, optimizing sleep structure to make it closer to the physiological sleep state. Clinical trials have shown that Lebrexan has a mild effect on patients’ memory and cognitive function, and does not significantly interfere with daytime activities (especially driving and other behaviors that require mental concentration). Studies have shown that the drug has ...
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is in full swing, and the original innovative drug LBL-024 from China has once again become the focus. The drug is a 4-1BB/PD-L1 bispecific antibody that is expected to fill the gap in the clinical treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). At the same time, positive efficacy signals have been observed in multiple cancer types such as small cell lung cancer and biliary tract cancer. It is worth noting that LBL-024 has entered the critical clinical trial stage. If approved, it will become the world’s first 4-1BB target drug, and will also make 4-1BB the world’s fourth druggable immune checkpoint after PD-1/L1, CTLA-4, and LAG3. 01 The world’s first! LBL-024 breaks through again The American Society of Clinical Oncology (ASCO) Annual Meeting is the world’s largest, most academically advanced and most authoritative clinical oncology conference, and the selected oral reports ...
Organiser: Reedsinopharm (a subsidiary of Sinopharm Group) Time:November 19-21, 2025 address:No. 300 Jiangdong Middle Road, Jianye District, Nanjing City, Jiangsu Province Exhibition hall:Nanjing International Expo Center Product range: Pharmaceuticals: Chemical drugs, traditional Chinese patent medicines, ethnic medicines, OTC drugs, and biological products. Pharmaceutical R&D Supply Chain: R&D services, CRO (Contract Research Organization), CMO (Contract Manufacturing Organization), CDMO (Contract Development and Manufacturing Organization), MAH (Marketing Authorization Holder) cooperation, and registration consulting. Chinese Herbal Medicine/Chinese Herbal Decoction Pieces: Bulk decoction pieces, traditional decoction pieces, refined packaged decoction pieces, small-package decoction pieces, directly ingestible solid decoction pieces, broken-wall decoction pieces, medicinal and edible Chinese herbal materials and herbal teas, Chinese herbal formula granules, novel Chinese herbal decoction pieces, production equipment for Chinese herbal materials and decoction pieces, packaging for Chinese herbal decoction pieces, etc. Traditional Chinese Medicine (TCM) Health Preservation: Moxibustion and moxibustion products, TCM health preservation centers, foot bath and foot ...
Drugdu.com expert’s response: Accelerated testing is a crucial method for assessing the stability changes of pharmaceuticals under short-term high-temperature and high-humidity conditions. It helps predict stability trends under long-term storage conditions and provides a basis for determining the shelf life and storage conditions of drugs. Below are the detailed steps and key points for conducting accelerated testing: I. Purpose of the Test The primary objective of accelerated testing is to accelerate the degradation or deterioration process of drugs within a relatively short period by elevating storage temperature and humidity conditions, thereby evaluating the stability of the drugs. II. Test Conditions Temperature: Typically, 40℃±2℃ is selected as the temperature condition for accelerated testing. This temperature, higher than the routine storage temperature, can expedite the degradation reactions of drugs. Humidity: The relative humidity is usually set at 75%±5%. High humidity conditions are beneficial for assessing the sensitivity of drugs to moisture. III. ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.